Supplementary Figure 2 Legend from Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines

Supplementary Figure 2 Legend - PDF file 58K, Supplementary Figure 2 legend: Effects on the downstream pathways by metformin treatment in A549 and H460. Western blotting analysis of AMPK, ACC, MAPK, AKT, p70S6K, S6, 4EBP1, activation following treatment with the indicated concentration of metformin. beta-actin was included as a loading control